ProfileGDS5678 / 1426726_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 65% 63% 67% 65% 64% 65% 64% 64% 65% 64% 66% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8701664
GSM967853U87-EV human glioblastoma xenograft - Control 23.8738165
GSM967854U87-EV human glioblastoma xenograft - Control 33.7820963
GSM967855U87-EV human glioblastoma xenograft - Control 44.0722867
GSM967856U87-EV human glioblastoma xenograft - Control 53.8995865
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8817464
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9650765
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8531564
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.831764
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8668565
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8599864
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9408366
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8709964
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8295364